Your browser doesn't support javascript.
loading
A novel tacrine-dihydropyridine hybrid (-)SCR1693 induces tau dephosphorylation and inhibits Aß generation in cells.
Wang, Xiu-Lian; Xiong, Yan; Yang, Yang; Tuo, Qing-Zhang; Wang, Xiao-Chuan; Chen, Rong; Tian, Qing; Zhang, Zheng-Ping; Yan, Xiong; Yang, Zhang-Yuan; Wang, Jian-Zhi; Liu, Rong.
Afiliação
  • Wang XL; Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; The Institute of Brain Research, Huazhong University of Science and Technology, Wuhan, China;
  • Xiong Y; Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; The Institute of Brain Research, Huazhong University of Science and Technology, Wuhan, China;
  • Yang Y; Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Tuo QZ; Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang XC; Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Chen R; Jiangsu Simovay Pharmaceutical Co., Ltd., Nanjing, China.
  • Tian Q; Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhang ZP; Jiangsu Simovay Pharmaceutical Co., Ltd., Nanjing, China.
  • Yan X; Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Yang ZY; Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang JZ; Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: wangjz@mails.tjmu.edu.cn.
  • Liu R; Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: rong.liu@hust.edu.cn.
Eur J Pharmacol ; 754: 134-9, 2015 May 05.
Article em En | MEDLINE | ID: mdl-25732864
ABSTRACT
AChE inhibitors are the first choice for the treatment of Alzheimer׳s disease (AD), but they could only delay the progression of cognitive and behavioral dysfunction, and fail to reverse neuronal damage. Calcium channel blockers have been identified to have protective effect on neurons. Thus, therapy targeting both AChE and calcium channels is supposed to be more effective in AD treatment. In the present study, we explored the effect of a synthesized juxtaposition of an AChE inhibitor and a Calcium channel blocker (named (-)SCR1693) on tau phosphophorylation and Aß generation. The results showed that (1) Compared with higher concentrations, (-)SCR1693 incubation in low concentrations such as 0.4, 2, 4µM for 24h did not affect the cell viability of HEK293/tau (HEK293 cells stably transfected with human tau40) and N2a/APP (N2a cells stably transfected with human APP) cells; (2) long-term treatment of cells with (-)SCR1693 (0.4, 2, 5µM) (24h) induced tau dephosphorylation and reduced the total tau level in HEK293/tau cells. Short-term treatment (6h) also resulted in tau dephosphorylation, but did not reduce the total tau level; and (3) (-)SCR1693 (0.4, 2, 4µM) incubation inhibited Aß generation and release dramatically in N2a/APP cells. We conclude that the novel tacrine-dihydropyridine hybrid (-)SCR1693 in low concentrations could reduce total and phosphorylated tau levels, inhibit the generation and release of Aß in cells. Thus, (-)SCR1693 may be a potential candidate for effectively treating AD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tacrina / Peptídeos beta-Amiloides / Proteínas tau Limite: Animals / Humans Idioma: En Revista: Eur J Pharmacol Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tacrina / Peptídeos beta-Amiloides / Proteínas tau Limite: Animals / Humans Idioma: En Revista: Eur J Pharmacol Ano de publicação: 2015 Tipo de documento: Article